Aethlon Medical agrees to merge with North Immunology to advance NOR-101, a bispecific antibody targeting atopic dermatitis. Read more now for investors.

Orbis Medicines partners with Novo Nordisk on oral cardiometabolic drug discovery in a deal worth up to $1.4 billion. Read ...

Matisse Pharmaceuticals has raised €14 million to advance isupartob sodium into a Phase II sepsis trial. Read the latest ...

Acelot has dosed the first volunteer in a Phase Ia trial of ACE-2223, an oral TDP-43 drug for ALS. Explore the trial, science ...

Penn researchers reveal how the NSD2–SETD2–EZH2 axis drives immune evasion in KRAS-driven lung cancer. Explore the Nature Communications findings now.

SK Biopharmaceuticals licenses global rights to Parkinson’s candidate 1ST-104 for up to $314.8 million. Read the deal details ...

Roche’s CELESTIMO study met its PFS endpoint in relapsed follicular lymphoma, strengthening Lunsumio’s path to full approval.

Novo Nordisk and Anthropic are joining forces to use Claude Science in drug discovery. Explore how the AI collaboration could accelerate future medicines.

SKY-0515 delivered a statistically significant 1.59-point cUHDRS advantage in Huntington’s disease—see what it means.

San Diego-based Aethlon Medical, Inc. (Nasdaq: AEMD) has agreed to merge with North Immunology, Inc. in an all-stock transaction that will take the atopic... South San Francisco-based Acelot has dosed ...

IASO208 wins FDA IND clearance for a U.S. trial in relapsed/refractory B-cell lymphoma. Explore IASO Bio’s in vivo CAR-T approach and potential now.

Sensorion confidentially filed for a potential US IPO as it advances GJB2 gene therapy for hearing loss. Read the full SEC filing and biotech outlook now.